CrownBio Demonstrates Scientific Advancements in Metabolic Disease with a validated and improved translatable model for obesity and Type 2 Diabetes drug discovery Taiwan Stock Exchange according to : GlobeNewswire

With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. These studies demonstrate that the FATZO model is a more translatable rodent model for obesity and type 2 diabetes, including for the development of anti-diabetic therapeutics. Media Enquiries: Jody Barbeau Crown Bioscience Inc. marketing@crownbio.com Charles Van Jackson, CSO CrownBio Indiana commented, "The FATZO mouse is an improved translatable model that provides us with a better understanding of the physiological and cellular mechanisms that lead from obesity, metabolic disorders, to diabetes. "These scientific advancements of translatable model development are the key to early discovery of disease and enable faster drug discovery."For more information on CrownBio's commitment to furthering the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmdAbout Crown Bioscience Inc.Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research.




Oral136 (002).JPG Michigan Medicine endocrinologist Elif Oral, M.D., leads clinical trial of asthma drug that shows promise as an obesity and diabetes medication. ANN ARBOR, Mich. -- After 12 weeks of taking an anti-inflammatory asthma drug, obese patients with type 2 diabetes showed a clinically significant drop in blood glucose. Blood sugar in the clinical trial patients went down as genes involved in the expenditure of energy changed. In the Cell Metabolism study, researchers identified a molecular signature in obese patients with type 2 diabetes who responded to the drug amlexanox. "It's a new mechanism for a diabetes and fatty liver drug.

After obesity drug flops, Arena Pharma plans a comeback. Will it work?

If you ask biotech investors today what they know about Arena Pharmaceuticals, nearly all will mention the weight-loss drug Belviq. Arena gave up on Belviq last January when it sold the rights to its Japanese partner, Eisai. With these new data, investors will get their first opportunity to assess Arena's comeback strategy. The first in the pipeline, targeting a rare and debilitating lung disease, will read out study results later this month. Now, the company is developing three new drugs ― none of which has anything to do with obesity.


collected by :Lucy William

To follow all the new news about Disease !!! All you need to know about all kinds of diseases